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Abstract
Background: Cystic fibrosis (CF) is caused by mutations in the gene encoding the cystic fibrosis transmembrane
conductance regulator (CFTR) protein, which acts as a chloride channel activated by cyclic AMP (cAMP). The most
frequent mutation found in 70% of CF patients is F508del, while premature stop mutations are found in about 10% of
patients. In vitro aminoglycoside antibiotics (e.g. gentamicin) suppress nonsense mutations located in CFTR permitting
translation to continue to the natural termination codon. Pharmacologic suppression of stop mutations within the CFTR
may be of benefit to a significant number of patients. Our pilot study was conducted to determine whether intravenous
gentamicin suppresses stop codons in CF patients and whether it has clinical benefits.
Methods: A dual gene reporter system was used to determine the gentamicin-induced readthrough level of the most
frequent stop mutations within the CFTR in the French population. We investigated readthrough efficiency in response
to 10 mg/kg once-daily intravenous gentamicin perfusions in patients with and without stop mutations. Respiratory
function, sweat chloride concentration, nasal potential difference (NPD) and CFTR expression in nasal epithelial cells
were measured at baseline and after 15 days of treatment.
Results: After in vitro gentamicin incubation, the readthrough efficiency for the Y122X mutation was at least five times
higher than that for G542X, R1162X, and W1282X. In six of the nine patients with the Y122X mutation, CFTR
immunodetection showed protein at the membrane of the nasal epithelial cells and the CFTR-dependent Cl- secretion
in NPD measurements increased significantly. Respiratory status also improved in these patients, irrespective of the
gentamicin sensitivity of the bacteria present in the sputum. Mean sweat chloride concentration decreased significantly
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and normalised in two patients. Clinical status, NPD and sweat Cl- values did not change in the Y122X patients with no
protein expression, in patients with the other stop mutations investigated in vitro and those without stop mutations.
Conclusion: Suppression of stop mutations in the CFTR gene with parenteral gentamicin can be predicted in vitro and
is associated with clinical benefit and significant modification of the CFTR-mediated Cl- transport in nasal and sweat gland
epithelium.
Background
Cystic fibrosis (CF) is caused by mutations in the gene
encoding the cystic fibrosis transmembrane conductance
regulator (CFTR) protein, which acts as a chloride channel
activated by cyclic AMP (cAMP) [1]. More than 1,500
mutations have been described since the discovery of the
gene, including premature stop mutations, which are
found in about 10% of all CF patients [2]. Pharmacologic
suppression of stop mutations within the CFTR gene may
therefore be of benefit to a significant number of patients.
In vitro, aminoglycoside antibiotics suppress nonsense
mutations located in the defective CFTR by disrupting
translational fidelity and thus permit translation to con-
tinue to the natural termination codon [3-5]. Moreover,
topical application of gentamicin to the nasal epithelium
of CF patients with stop mutations restores CFTR function
and increases CFTR membrane immunostaining [6].
However, preliminary clinical trials with intravenous gen-
tamicin failed to demonstrate any improvement in
patients, suggesting that this molecular effect would not
lead to a clinical benefit [7,8]. The variety of mechanisms
that modulate readthrough activity may explain this lack
of efficacy. Most importantly, the stop codon itself and its
surrounding sequences cause variations in the level of
gentamicin-induced readthrough [9].
To take these considerations into account, we conducted
a two-step study. Using a dual reporter gene assay, we first
determined the readthrough level of the most prevalent
stop codon mutations in the French CF population after
gentamicin incubation. We then focused on the muta-
tions with the best in vitro response. To investigate
readthrough efficiency after intravenous gentamicin in CF
patients with these mutations, in comparison with
patients with other stop mutations and without stop
mutations, we tested CFTR expression in nasal cells, eval-
uated the CFTR-mediated chloride secretion in nasal and
sweat gland epithelia, and assessed clinical status.
Methods
Readthrough quantification in cell culture
A dual gene reporter system was used to quantify the
readthrough efficiency directed by the most frequent stop
mutations in the French population (Y122X, G542X,
R1162X and W1282X) [10], in the presence or absence of
gentamicin. It has been previously demonstrated that for
a given mutation, the readthrough levels obtained with
this experimental system are similar to those obtained in
vivo[11]. With this dual reporter, all the ribosomes that
initiate translation give rise to β-galactosidase activity,
while only those that read through the stop codon lead to
luciferase activity. The use of a dual reporter allows inter-
nal calibration of transfection efficiency, transcription rate
of the reporter gene, stability of the message and transla-
tion initiation efficacy between independent experiments.
A 100% activity control was provided by a construct (TQ)
with no stop codon between the coding sequences of the
two reporters. Corresponding complementary oligonucle-
otides were annealed and cloned between the lacZ and luc
coding sequences in the pAC99 vector (Table 1) [11].
NIH3T3 cells were electroporated with 20 μg of amplified
plasmid and incubated with or without gentamicin at a
concentration of 600 μg/ml. This concentration has previ-
ously been shown to be optimal for readthrough induc-
tion while being non-toxic during the length of the
treatment in a pilot experiment where concentrations
ranging from 100 to 1,200 μg/ml where tested on NIH3T3
cells ([11] and Bidou L and Rousset JP, unpublished
results). Following transfection, cells were rinsed every
day and fresh medium supplemented with antibiotic was
added. After three days of expression, cells were harvested
and lysed, and β-galactosidase and luciferase enzymatic
activities were assayed. The readthrough efficiency was
estimated by the ratio of luciferase to β-galactosidase
activity obtained with the test construct and normalised
with the ratio obtained with the in frame control con-
struct.
Treatment protocol
The study was approved by the Necker-Enfants Malades
Ethics Committee, and written informed consent was
obtained for each subject. Exclusion criteria were abnor-
mal baseline hearing or kidney function, nasal polyps,
upper respiratory tract infection and treatment by either
parenteral or inhaled aminoglycosides in the previous
month. The ethics committee refused to authorise inclu-
sion of a control group of patients treated with placebo,
holding the opinion that, given the obvious lack of bene-
fit to these patients, the benefits of having a placebo group
did not justify their exposure to the risk of parenteral per-
fusions.BMC Medicine 2007, 5:5 http://www.biomedcentral.com/1741-7015/5/5
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CF patients were treated for 15 days with intravenous gen-
tamicin, administered once daily at 10 mg/kg infused for
30 minutes. Gentamicin trough (24 hours after infusion)
and peak (after 30 minutes infusion ended) levels were
measured on the third day. The dose was then adjusted to
achieve peak serum levels between 20 and 40 μg/ml and
trough levels <2 μg/ml. Gentamicin toxicity was moni-
tored before the study and at midpoint by measuring
serum creatinine concentrations and by audiometric stud-
ies, including pure-tone air conduction threshold and
high-frequency tones.
Treatment endpoints
Clinical evaluation took place the day before gentamicin
treatment began (day 0) and the day after it ended (day
15). The Cystic Fibrosis Clinical Score (CFCS), based on
pulmonary, nutritional evaluation and temperature [12],
was used to assess clinical status. This score has been vali-
dated to evaluate modification of clinical parameters. It
includes five common symptoms (cough, sputum pro-
duction, appetite, shortness of breath, and energy level)
and five physical findings (temperature, respiration rate,
weight, air exchange and crackles). It is graded on a five-
point scale for a maximum severity score of 50 points. A
decrease of 10 points is considered clinically relevant.
Forced expiratory volume (FEV1), forced vital capacity
(FVC), and forced expiratory flow at 25 to 75 percent of
vital capacity (FEF25–75) were expressed as percentages of
predicted values for age, sex, and height. Patients had not
been treated for 8 hrs with β2-mimetics before performing
respiratory function explorations. An increase of 7.5% for
any of the three tests was considered significant.
Transepithelial nasal potential difference (NPD) was
measured according to the procedures described by
Knowles and collaborators [13]. Baseline NPD was meas-
ured after perfusion of nasal epithelium with saline solu-
tion, and NPD changes were recorded after perfusion with
the following solutions: 100 μM amiloride in saline solu-
tion to block sodium current (Δamiloride), chloride-free
solution with 100 μM amiloride (ΔCl-free) and chloride-
free solution with 100 μM amiloride and 10 μM isoprot-
erenol (Δisoproterenol). The sum of ΔCl-free and Δisopro-
terenol (ΔCl-free-isoproterenol) reflects the cAMP
activation of nasal mucosa chloride permeability and
served as the indicator of transepithelial CFTR-dependent
chloride transport.
CFTR immunocytochemistry
CFTR expression in nasal epithelial cells was assessed with
24-1 (R & D Systems, Lille, France) and MATG 1061 (gift
from Transgène, Strasbourg, France) monoclonal anti-
bodies before and after gentamicin treatment. These anti-
bodies recognise amino acids 1377–1480 at the C-
terminus and amino acids 503–515 in the first nucle-
otide-binding domain of CFTR, respectively and were
chosen as they are accurate to detect CFTR in nasal epithe-
lial cells by immunocytochemistry [14]. Cells were
obtained by nasal brushing below the middle turbinate
from the CF patients who agreed to furnish these samples
and from two healthy controls thoroughly genotyped for
the CFTR gene. Cells were spread on slides and fixed at
4°C in acetone for 10 min and then in 4% paraformalde-
hyde for 20 min. They were then incubated in 10% acetic
acid for 10 min. After blockage of nonspecific binding
sites with 0.1% TBS, 3% Tween 20, 10% bovine serum
albumin-normal human AB serum, cells were incubated
for 1 hr with 24-1 or MATG 1061 monoclonal antibodies
diluted 1:100 and 1:1,000, respectively. They were then
incubated with biotinylated goat-antimouse IgG (Dako,
Trappes, France) diluted 1:600 and then with streptavi-
din-alkaline phosphatase conjugate (Dako, Trappes,
France). Enzymatic activity was visualised with Fast Red/
naphtol (Sigma Aldrich, St Quentrin Fallavier, France).
Table 1: Oligonucleotide sequences used in the dual reporter gene assay, corresponding to the Y122X, G542X, R1162X and W1292X 
mutations and the TQ in frame control. Readthrough level before and after incubation with 600 μg/ml gentamicin.
Readthrough level (%)*
Mutation Oligonucleotides** 0 600 μg/ml gentamicin
Y122X w 5' CGCTCTATCGCGTAACTAGGCATAGGC 3';
c 5' GCCTATGCCTAGTTACGCGATAGAGCG 3'
0.52 1.6
W1282X w 5’ AATATAGTTCTTTGAGAAGGTGGAATC 3’
c 5’ GATTCCACCTTCTCAAAGAACTATATT 3’
0.115 0.35
R1162X w 5' CGATCTGTGAGCTGAGTCTTTAAGTTC 3';
c 5' GAACTTAAAGACTCAGCTCACAGATCG 3'
0.023 0.22
G542X w 5' ACTTTGCAACAGTGAAGGAAAGCCTTT 3';
c 5' AAAGGCTTCCTTCACTGTTGCAAAGT 3'
0.017 0.26
TQ: in frame control w 5' GCAGGAACACAACAGCAATTACAG 3'
c 5' CTGTAATTGCTGTTGTGTTCCTGC 3'
100 100
*At least five independent experiments were performed with each construct and showed less than 20% variation.
** w and c refer to the sense and antisense strands respectively.BMC Medicine 2007, 5:5 http://www.biomedcentral.com/1741-7015/5/5
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Slides were then washed, counterstained with hematoxy-
lin and mounted in aqueous medium. Negative controls
were obtained by using an isotype-matched mouse non-
immune IgG2 instead of the primary antibody. Two inves-
tigators blinded to the patients' data examined all slides.
Patients were considered positive for CFTR expression
when positive staining at the membrane was observed in
at least 10% of the cells examined with at least one anti-
body.
Statistical analysis
Data are presented as mean (SD). Data between day 0 (D
0) and day 15 (D 15) were compared with the nonpara-
metric Wilcoxon test. Groups were compared with the
nonparametric Mann-Whitney test for quantitative varia-
bles. Correlation coefficients were calculated with the
Spearman correlation test.
Results
Quantification of the readthrough level in cell culture
Basal and gentamicin-induced readthrough levels are
shown in Table 1. The R1162X and the G542X mutations
yielded basal readthrough of less than 0.03% and
increased by a factor of 10 and 15 respectively after gen-
tamicin. The basal readthrough of W1282X was ~10 times
higher than those of R1162X and G542X and tripled after
gentamicin. Y122X had a basal readthrough level five
times higher than that for the W1282X mutation, 22 times
that for R1162X and 30 times that for G542X. After gen-
tamicin incubation, Y122X readthrough efficiency
remained at least 4.5 times higher than that for W1282X,
six times that for G542X and 7.3 that for R1162X. We
therefore decided to focus the clinical trial on patients
with the Y122X mutation.
Patients
Table 2 summarises the characteristics of the 18 study
patients. Nine carried the Y122X mutation (eight were
Y122X homozygous and one was Y122X/F508del)
(Group A). Four had another stop mutation: one was
homozygous for G542X, one for R1162X, and two were
compound heterozygous for W1282X/F508del and
R553X/CFTRdele17b (Group B). In addition, five patients
without stop mutations were studied according to the
same protocol and served as a control group. Three were
F508del homozygous, and the other two were compound
heterozygous for F508del and class 2 mutations (Group
C). There were no significant differences between the
three groups for pulmonary status or gentamicin sensitiv-
ity of the bacterias in the patient's sputum.
Clinical response and tolerance
Modification of clinical scores and respiratory function
are shown in Tables 3 and 4. Clinical scores for the nine
patients with the Y122X mutation (Group A) improved
significantly at the end of the study, mainly because of
improvements in coughing, sputum production, dyspnea
and energy level. Even among the patients with the most
severe symptoms, these changes were noted as early as the
fourth day of treatment. Pulmonary function also
improved significantly for FEV1 and almost at the signifi-
cant level for FVC and FEF25–75 (p = 0.09). These changes
were not correlated with microbiological sensitivity to
gentamicin. Four of the five patients with significant
improvement had bronchial colonisation with gen-
tamicin-resistant bacterias. The most impressive effects
were observed in a patient with severe pulmonary disease
and bronchial colonisation with a gentamicin-resistant
Burkholderia cepacia strain. He showed substantial clinical
improvement (far greater than with the standard antibi-
otic treatment) with much less coughing and dyspnea and
a considerable fluidification of his sputum. At the end of
the trial, he had gained 1.5 kg, and his FEV1 had improved
by 19%, FVC by 24%, and FEF25–75 by 150% (line 7 in
Table 3).
Neither clinical scores nor respiratory functions changed
significantly among the patients with other stop muta-
tions (Group B) or among controls (Group C).
Mid-study renal function testing and audiometric studies
showed no significant changes from baseline. The mean
peak and trough serum gentamicin levels were in the tar-
get range for all the patients as early as the third day.
Sweat test
Initial sweat chloride levels were typical for CF patients,
that is > 60 mM/L. These levels decreased significantly
after treatment among patients with the Y122X mutation
(Group A) (Tables 3 and 5; Figure 1). Values normalised
in two patients to levels < 60 mM/L, and for another, the
value fell from 114 mM/L to 65 mM/L. One week after the
study ended in these three patients, sweat chloride con-
centrations had returned to levels above 75 mM/L,
thereby indicating that the gentamicin-induced change
did not persist after discontinuation of treatment. There
was no significant modification of the sweat chloride val-
ues in the two other groups (Table 5).
Nasal potential difference
NPD values before treatment were typical of CF patients,
i.e., highly negative basal NPD, strong depolarisation in
response to inhibition of sodium current by 100 μM ami-
loride (Δamiloride) and no significant response to CFTR
activation by isoproterenol 10 μM in chloride-free solu-
tion (ΔCl-free-isoproterenol) [13] (Figure 2a, Tables 3 and
5). Treatment with gentamicin for 15 days decreased the
basal NPD (p = 0.12) and the amplitude of the amiloride-
induced depolarisation (p = 0.09), but this did not reach
the significance level (Group A, Table 5). IsoproterenolBMC Medicine 2007, 5:5 http://www.biomedcentral.com/1741-7015/5/5
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perfusion in chloride-free solution significantly hyperpo-
larised NPD, from -0.8(1.3) mV to -4.6(6) mV (p = 0.04)
(Table 3 and Group A, Table 5). Recordings taken at the
end of the study generally showed a stable pre-isoprotere-
nol baseline during low chloride solution perfusion, fol-
lowed by hyperpolarisation after isoproterenol was added
(Figure 2b). There was a significant negative correlation
between the changes of Δamiloride and of ΔCl-free-iso-
proterenol. (ρ = -0.9; p = 0.01; Spearman correlation test).
These results are consistent with the restoration of a CFTR-
dependent secretory chloride transport in the nasal epi-
thelium. Changes in the sweat chloride concentration and
response to isoproterenol were not correlated (ρ = 0.17; p
= 0.66).
In contrast to the patients with the Y122X mutation, the
patients with other stop mutations (Group B) and those
without any stop mutations (Group C) had no significant
modifications of their basal potential difference or
response to amiloride or isoproterenol (Table 5).
CFTR immunodetection in nasal epithelial cells
The analysis of CFTR expression with the 24-1 and MATG
1061 antibodies were all concordant. The effect of
parenteral gentamicin on CFTR was analysed in patients
who agreed to nasal brushing, i.e., seven Y122X
homozygous patients, one compound F508del/Y122X
patient, one R1162X homozygous patient, and the five
patients without stop mutations. Before gentamicin treat-
ment, no CFTR labeling was observed in any of the Y122X
homozygous patients (see representative picture in Figure
2c), while afterwards, five patients expressed CFTR at the
membrane in 10 to 80% of cells (Figure 2d). These five
patients were considered responders. The staining pattern
did not change for two patients after treatment. Before
treatment, cytoplasmic labeling in the compound hetero-
zygous Y122X/ΔF508 patient was found in 20% of the
cells with 24-1 antibody and 70% of the cells with MATG
1061 antibody and, after treatment, in 70% and 100% of
the cells, respectively. This patient was considered a
responder. Among the Y122X responders, CFTR-depend-
Table 3: Characteristics of the subjects with stop codon mutations and variation of clinical and functional parameters after treatment 
with gentamicin.
Genotype Sputum 
colonisation
Age (year) Δscore FEV1var FVCvar FEF25–75var Sweat Cl- at 
D0
Sweat Cl- at 
D15
ΔCl-free-iso 
at D0
ΔCl-free-iso 
at D15
ICC
Y122X+/+ SA 11 -4 24 23 31 126 91 0 0 -
Y122X+/+ PA* 16 -2 -12 -6 -15 79 37 NP 0 -
Y122X+/+ PA*,SA 18 -4 2 -2 -8 109 115 0 NP +
Y122X+/+ PP* 15 -5 25 19 86 90 91 -0.5 0 +
Y122X+/+ PP* 13 -15 18 8 96 103 46 -1.6 -3.8 +
Y122X+/+ SA 22 -13 3 0 7 108 100 -3.7 -17.6 +
Y122X+/+ BC* 21 -22 18 24 150 136 135 0 -4 +
Y122X+/+ PA* 12 -12 3 -9 NP 119 86 0 -8.2 NP
Y122X+/F508del SA* 10.5 -3 21 21 45 114 65 -1 -3.3 +
R1162X +/+ SA 14 -2 0.4 0 4 116 131 0 0 -
F508del/W1282X PA 13 -2 15 14 27 103 100 0 -1.3 NP
G542X +/+ SA 11 -4 21 17 20 113 105 0 0 NP
R553X/CFTRdele17b PA* 10 0 NP NP NP 115 NP -4 NP NP
PA: Pseudomonas aeruginosa; SA: Staphylococcus aureus; PP: Pseudomonas putida; BC: Burkholderia cepacia; * bacteria resistant to gentamicin. FEV1var 
refers to the ratio (FEV1D15~FEV1D0)/FEV1D0; FVCvar refers to the ratio (FVCD15~FVCD0)/FVCD0. FEF25–75var refers to the ratio (FEF25–
75(D15)~FEF25–75(D0))/FEF25–75(D0). Δscore refers to value of CFCSD15-CFCSD0. ΔCl-free-iso refers to ΔCl-free-isoproterenol. ICC: 
immunocytochemistry. NP: not performed.
Table 2: Characteristics of the study subjects.
Patients Group A
n = 9
Group B
n = 4
Group C
n = 5
p
Group A vs. B
p
Group A vs. C
p
Group B vs. C
Age 15.4(4.2) 12(1.8) 16.5(1.7) NS NS NS
CFCS 31(8) 26(2) 24(2) NS NS NS
FEV1 (%) 69(21) 80(12) 74(10) NS NS NS
FVC (%) 70(20) 83(7) 84(22) NS NS NS
FEF25–75 (%) 46(30) 67(26) 54(26) NS NS NS
Group A: patients with the Y122X stop mutation. Group B: patients with another stop mutation. Group C: patients without any stop mutation. 
CFCS refers to the Cystic Fibrosis Clinical Score. FEV1, FVC, FEF25–75 refer respectively to forced expiratory volume in one second, forced vital 
capacity, and forced expiratory flow at 25 to 75 percent of vital capacity and are expressed as percentages of predicted values for age, sex, and 
height. NS: non-significant. Data are described as mean (SD)BMC Medicine 2007, 5:5 http://www.biomedcentral.com/1741-7015/5/5
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ent chloride secretion increased after treatment from -
1.1(1) to -5.8(6) (p = 0.06) and remained absent for the
two non-responders. Disease also improved among
responders. CFCS variation between the two evaluations
was -10(7) in the responders versus -2(1) for the non-
responders (p = 0.04).
The R1162X patient had no CFTR labeling either before or
after treatment (data not shown). The patients without
any stop mutation (group C) had only cytoplasmic CFTR
staining, a pattern that did not change after treatment
(data not shown). Both the R1162X homozygous patient
and the group C patients were considered non-respond-
ers.
Seric and sputum concentrations were higher in the
responder patients (respectively 25.8(2) μg/mL versus
20.6(3.3) μg/mL, p = 0.05; and 2.4(1.4) μg/mL versus
1.7(1.3) μg/mL, NS).
Overall, the pattern of the in vitro readthrough, clearly
most efficient for the Y122X mutation, was strongly corre-
lated with the immunocytochemically determined CFTR
expression in nasal cells, as assessed by the CFTR staining
after treatment for the Y122X patients, compared with the
lack of staining in both the R1162X patient and the
patients without stop mutations.
Discussion
This open study shows that intravenous delivery of gen-
tamicin at a clinically safe dose can induce readthrough of
stop codons. In patients carrying the Y122X mutation,
gentamicin treatment resulted in delivery of the CFTR pro-
tein at the membrane and in restoration of CFTR-depend-
ent chloride transport in nasal epithelial cells. These
changes were correlated with improved respiratory status,
thus providing evidence that this pharmacologic therapy
may be clinically beneficial. Most interestingly, the clini-
cal, electrophysiological and immunological responses
were observed in the patients carrying the mutation that
responded best in a reporter gene assay system. This dem-
onstrates that this pharmacologic therapy is mutation-
specific and that in vitro assays are a useful tool for target-
ing patients who would benefit from this treatment.
Few studies of CF patients have investigated the potential
benefit of gentamicin treatment to suppress premature
termination codons, although this mechanism has
already been demonstrated in vitro [4,5] and in animal
models [15]. Wilschanski et al, found that topical admin-
istration of gentamicin to the nasal epithelium signifi-
cantly increased the response of patients with stop
mutations to chloride-free isoproterenol solution and the
nasal cells CFTR surface staining [6]. Clancy et al tested its
systemic effect by treating five CF patients heterozygous
for stop mutations with parenteral gentamicin (2.5 mg/kg
three times a day) for seven days [7]. The patients with
stop mutations had a significantly higher proportion of
NPD readings with chloride secretion than the control
group with no stop mutations. Sweat tests and lung
spirometry did not improve significantly, however. One
explanation for the differences between the two studies
might be the difference in gentamicin dosage. In the
Clancy study, gentamicin dosing was adjusted to achieve
peak seric levels from 8 to 10 μg/ml with administration
of 2.5 mg/kg three times a day, whereas we aimed peak
concentrations from 20 to 40 μg/ml with administration
of 10 mg/kg once a day, a dosage regimen known to
achieve higher serum concentrations in CF patients with-
out toxic effects. The higher serum concentrations
obtained in our study were very likely associated with
higher sputum concentrations, because aminoglycoside
penetration into bronchial secretions depends on the
once daily dose and on the peak serum concentration
[16]. This point is important because suppression of stop
mutations is dose dependent. This is supported by in vitro
studies showing that the concentration of full-length
CFTR protein after incubation with gentamicin of cells
harbouring stop mutations parallels the increase in the
antibiotic dose [4]. Studies in mdx mice, an animal model
for muscular dystrophy, also linked to a stop mutation,
further demonstrated that the level of the serum peak was
Table 4: Modification of clinical score and respiratory function tests after gentamicin treatment.
Group A
n = 9
Group B
n = 4
Group C
n = 5
D0 D15 p D0 D15 p D0 D15 p
CFCS 30(8) 21(8) 0.007 25(1) 22 (1) NS 23.5(2) 23(3) NS
FEV1(L) 1.82(0.8) 2.07(0.8) 0.04 1.68(0.4) 1.77(0.3) NS 2(0.3) 2.12(0.4) NS
FVC(L) 2.2(1) 2.36(0.9) NS 2.08(0.6) 2.14(0.5) NS 2.93(0.5) 3(0.4) NS
FEF25–75(L) 1.54(1.1) 1.95(1.06) NS 1.91(0.9) 1.96(0.8) NS 1.93(1.8) 1.99(1.8) NS
Group A: patients with the Y122X stop mutation. Group B: patients with another stop mutation. Group C: patients without any stop mutation. 
CFCS refers to the Cystic Fibrosis Clinical Score. FEV1, FVC, FEF25–75 as defined in Table 2 and are expressed as absolute values. Data are described 
as mean (SD). Comparison with Wilcoxon test.BMC Medicine 2007, 5:5 http://www.biomedcentral.com/1741-7015/5/5
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a determinant factor for gentamicin efficacy because mis-
translation did not occur below a certain level and was
correlated to the antibiotic dose [17]. The fact that seric
and sputum concentrations were higher in the responder
patients in our study supports the assumption that high
concentrations in bronchial secretions might favor the
mechanism of readthrough. We therefore hypothesise
that a critical concentration is needed to obtain significant
readthrough and propose that future clinical studies
measure the gentamicin concentration in contact with the
target cells to identify the concentration that best pro-
motes useful preferential misreads. We cannot exclude the
Table 5: Modification of the sweat test and the NPD results after gentamicin treatment.
Group A
n = 9
Group B
n = 4
Group C
n = 5
Patients D0 D15 p D0 D15 p D0 D15 p
Sweat chloride (mM/L) 109(17) 85(31) 0.03 110(7) 112(16) NS 96(1.5) 105(18) NS
Basal PD -56(10) -49(5) 0.12 -53(11) -50(8) NS -52(8) -52(7) NS
ΔAmiloride 20(6) 15(7) 0.09 22(15) 20(9) NS 19(12) 21(13) NS
ΔCl-free-isoproterenol -0.8(1.3) -4.6(6) 0.04 -0.2(0.5) -0.9(1) NS 0(0.5) -0.8(1) NS
Group A: patients with the Y122X stop mutation. Group B: patients with another stop mutation. Group C: patients without any stop mutation. 
Data are described as mean (SD). Comparison with Wilcoxon test.
Sweat chloride concentration and ΔCl- free-isoproterenol before and after gentamicin in Y122X patients (●) Figure 1
Sweat chloride concentration and ΔCl- free-isoproterenol before and after gentamicin in Y122X patients (●). 
Previously published representative data of healthy controls (❍) are shown [27].
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possibility that the respiratory improvement shown in our
patients was due to an antimicrobial effect, even in
patients with microorganisms resistant to gentamicin,
because of the frequently seen discrepancy between in
vitro drug sensitivity and in vivo clinical response. How-
ever, the fact that patients without any stop mutations did
not improve significantly, even those with sensitive
strains, provides strong evidence for a clinical effect linked
to codon stop suppression rather than to an antibiotic
effect. Although there was a correlation in patients carry-
ing the Y122X mutation between the decrease of the
response to amiloride (sodium absorption) and the
increase of the response to isoproterenol (CFTR depend-
ent chloride secretion), there was only a trend in the
decrease of the response to amiloride, the non-significant
level probably being due to the small sample of patients.
In contrast, patients with mutations producing lower lev-
els of translational readthrough in the cell culture assay
(G542X, R1162X and W1282X) did not show significant
changes in clinical status, chloride secretion in either the
nasal or sweat gland epithelia after gentamicin treatment.
Interestingly, the R1162X patient did not have positive
protein immunostaining at the end of the treatment, dem-
onstrating a correlation between proteic expression and
Example of nasal potential difference tracing (NPD) (a, b) and CFTR immunostaining with MATG 1061 monoclonal antibody of  nasal ciliated cells (c,d) before (a,c) and after (b,d) parenteral gentamicin treatment in a Y122X homozygous CF patient Figure 2
Example of nasal potential difference tracing (NPD) (a, b) and CFTR immunostaining with MATG 1061 mono-
clonal antibody of nasal ciliated cells (c,d) before (a,c) and after (b,d) parenteral gentamicin treatment in a 
Y122X homozygous CF patient. In (d), insert of nasal epithelial cells from a healthy control subject. Scale bars are 40, 20 
and 60 microns for (c), (d) and insert, respectively. (a) NPD before treatment showed a basal NPD of -50 mV, strong depolari-
sation in response to 100 μM amiloride (25 mV), and no significant response to CFTR activation by 10 μM isoproterenol in 
chloride-free solution. (b) At the end of treatment, basal PD was close to -45 mV, amiloride-induced depolarisation had not 
changed, and addition of isoproterenol in chloride-free solution induced hyperpolarisation of ~ -5 mV, indicating a CFTR-
dependent chloride transport. (c) No CFTR labeling was observed before treatment. (d) After gentamicin treatment, CFTR 
labeling was detected in the patient's nasal cells.
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functional pattern. Systemic administration of gentamicin
also significantly modified sweat chloride concentrations,
an infrequently seen effect in CF. The absence of correla-
tion between the sweat test, CFTR expression, and func-
tion in nasal cells suggests that gentamicin may have
different effects on the sweat duct and the respiratory epi-
thelial cell. Parenteral gentamicin may be delivered in
lower quantities to sweat glands than to the nasobron-
chial epithelium. Moreover, sweat tests may not be sensi-
tive enough to detect small changes in CFTR activity.
The originality of our study resides in a multidisciplinary
pharmacogenetic approach that allowed us to evaluate the
readthrough efficiency first in vitro with a dual reporter
gene assay and then in CF patients, by measuring clinical,
functional, and immunological parameters. Clinical
responses for each patient could therefore be interpreted
in the light of the level of the gentamicin-induced transla-
tional readthrough and the demonstration that the pro-
tein synthesised was functional. Thus, as our group is
genetically homogeneous, our results are quite convinc-
ing, despite the small number of patients.
As stop codons show a broad spectrum of readthrough
efficiency in response to gentamicin, we first investigated
in culture cells the response to gentamicin of the most fre-
quent stop mutations encountered in French CF patients.
The readthrough efficiency for the Y122X mutation, a
nonsense mutation mainly found among inhabitants of
the Reunion Island and resulting in an ochre termination
codon (UAA) [18], was at least five times higher than that
for the other CFTR stop mutations tested and more gener-
ally, 10 to 40 times higher than that for other previously
tested TAA-coded mutations [11]. Several studies have
shown that UAA stop codons yield the lowest
readthrough levels, with or without gentamicin [19]. The
high readthrough levels observed for the Y122X mutation,
both basal and induced, suggest that the nucleotide envi-
ronment of the stop codon may overcome the strong ter-
mination efficiency directed by the UAA codon. The +4C
nucleotide could account for the better response to gen-
tamicin, because it is associated with greater readthrough
efficiency, whereas the other mutations tested in our
study, R1162X and G542X, imply a +4G nucleotide,
which is associated with a poor readthrough [11]. As the
readthrough levels obtained with this experimental sys-
tem for a given mutation are similar to those obtained in
vivo [11], these results suggested that patients with the
Y122X mutation may benefit from gentamicin treatment.
We therefore decided to focus the clinical study on
patients homozygous for the Y122X mutation and com-
pare them with a group of patients with the other stop
mutations we tested in vitro, and a control group of
patients with no stop mutations.
Clinical response was interpreted in correlation with
CFTR expression and the evaluation of the function of the
newly synthesised protein. This point is important as
some readthroughs may generate complete but not func-
tional proteins. Cell membrane staining with an antibody
that recognises the C terminal region of CFTR demon-
strated that gentamicin treatment of CF patients with the
Y122X mutation can induce the readthrough of this stop
mutation and the synthesis of a full-length CFTR protein
delivered at the membrane. This "induced" CFTR protein
was functional, as demonstrated by the significant
increase in the cAMP-dependent chloride secretion of the
responders compared with non-responders. It is likely
that a low level of CFTR is sufficient to restore normal air-
way epithelial function, as suggested by the significant
change in nasal CFTR-dependent chloride transport in
patients with CFTR expression after gentamicin treatment
in as few as 10% of their cells. These results are consistent
with previous studies showing that the CFTR gene in nor-
mal individuals is expressed at low levels of 1–2 tran-
scripts per cell in the epithelium of the nose, trachea, and
bronchi [20] and that a low level of normal CFTR is suffi-
cient to restore normal airway epithelial function in gene
transfer experiments [21,22]. The absence of response to
gentamicin in two of the Y122X patients enrolled may be
due to inefficient uptake or distribution of gentamicin in
patients' bronchial secretions, depending on individual
pharmacokinetic characteristics, but also to inefficiency at
any step during the complex mechanism of stop codon
readthrough [23]. One explanation could be a variable
efficiency of the nonsense-mediated mRNA decay (NMD)
pathway in response to gentamicin treatment. Indeed, a
considerable variability in the level of CFTR nonsense
transcript was found among the patients carrying the
W1282X mutation and receiving a topical administration
of nasal gentamicin, with a significant correlation
between the amount of CFTR nonsense transcripts and the
modification of CFTR function after treatment [24].
Conclusion
Although our data concern only the Y122X genotype, a
rare mutation, they can theoretically be generalised. They
demonstrate for the first time that pharmacological sup-
pression of CFTR premature stop mutations can restore
adequate levels of functional protein and therefore
improve the clinical status of CF patients. Moreover, the
correlation between the readthrough levels in cell culture
and in vivo efficiency in a genetically homogeneous group
suggests that clinical trials aimed at suppressing stop
mutations should be preceded by in vitro studies to target
the patients most likely to benefit from this pharmaco-
logic therapy. It provides evidence for the potential for
pharmacological therapy in patients with stop mutations.
Encouraging results have been recently obtained in CF
with amikacin [25] as well as PTC124 [26], a promisingBMC Medicine 2007, 5:5 http://www.biomedcentral.com/1741-7015/5/5
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new drug that, unlike aminoglycosides, has rare and mild
side effects. This less-toxic compound might allow phar-
macologic therapy to start with diagnosis. These results
hold great promise for the treatment of a subset of
patients with CF and other diseases caused by premature
stop codons.
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